Free Trial
OTCMKTS:EMBI

Emerald Bioscience (EMBI) Stock Price, News & Analysis

$0.09
+0.00 (+1.69%)
(As of 01/15/2021)
Today's Range
$0.09
$0.10
50-Day Range
$0.09
$17.75
52-Week Range
$0.02
$0.20
Volume
6.96 million shs
Average Volume
14.24 million shs
Market Capitalization
$24.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EMBI stock logo

About Emerald Bioscience Stock (OTCMKTS:EMBI)

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.

EMBI Stock Price History

EMBI Stock News Headlines

See More Headlines
Receive EMBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emerald Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:EMBI
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$1.05 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$24.13 million
Optionable
Not Optionable
Beta
0.43
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Punit S. Dhillon B.A. (Age 40)
    BA, Exec. Chairman & CEO
    Comp: $65k
  • Mr. Richard Janney
    Interim Principal Accounting Officer
  • Ms. Elena Traistaru (Age 61)
    Company Sec.

EMBI Stock Analysis - Frequently Asked Questions

How have EMBI shares performed in 2024?

Emerald Bioscience's stock was trading at $2.72 on January 1st, 2024. Since then, EMBI shares have decreased by 96.7% and is now trading at $0.09.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Emerald Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emerald Bioscience investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Charlotte's Web (CWBHF), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cognex (CGNX), Cumberland Pharmaceuticals (CPIX), Corbus Pharmaceuticals (CRBP) and Editas Medicine (EDIT).

How do I buy shares of Emerald Bioscience?

Shares of EMBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EMBI) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners